Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152465 | 0.89 | VNN1 (0.53) | VNN1GRM4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL14542864 | 0.77 | KCNQ3 (0.65) | VNN1GRM4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL23458490 | 0.74 | KCNMA1 (0.52) | NPC1RAB9AHTTALDH1A1LMNA | |
| SCHEMBL1923606 | 0.74 | PDE4D (0.42) | VNN1GRM4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL13812239 | 0.72 | LMNA (0.41) | VNN1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL28253118 | 0.71 | S1PR3 (0.46) | VNN1GRM4HTTS1PR3S1PR1 | |
| SCHEMBL20185806 | 0.70 | VNN1 (1.00) | VNN1 | |
| SCHEMBL15867032 | 0.69 | VNN1 (0.56) | VNN1GRM4S1PR3MAPT | |
| SCHEMBL6869441 | 0.68 | S1PR3 (0.52) | S1PR3S1PR1LMNAS1PR4S1PR2 | |
| SCHEMBL8129368 | 0.68 | MAPK3 (0.44) | VNN1GRM4S1PR3S1PR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219319-A1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | Nippon Chemiphar Co., Ltd. (JP) | 2017-09-20 | — | — | EP | disclosed |
| EP-2036561-B1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | NIPPON CHEMIPHAR CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-8314085-B2 | Agent for overcoming resistance to anti-cancer agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110257201-A1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20100234399-A1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-2036561-A1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | Nippon Chemiphar Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1911760-A1 | XANTHINE OXIDASE INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911760-A1 | XANTHINE OXIDASE INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | XDH, PNPO, CBR1 | VNN1 1757/4885GRM4 4605/4885KCNQ3 2704/4885 |
| US-20100234399-A1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | TMX1, TPX2, XDH | VNN1 1213/4885GRM4 2360/4885KCNQ3 1783/4885 |
| US-20110257201-A1 | AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT | TMX1, TPX2, XDH | VNN1 1213/4885GRM4 2360/4885KCNQ3 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.